| Initial public offer of up to 16,08,000 equity shares of face value of Rs. 10/- each ("The Equity Shares") of Avience Biomedicals Limited ("The Company" or "ABL" or The "Issuer") at an issue price of Rs. [*] per equity share for cash, aggregating up to Rs. [*] crores ("Public Issue") out of which 80,400 equity shares of face value of Rs. 10/- each, at an issue price of Rs. [*] per equity share for cash, aggregating Rs. [*] crores will be reserved for subscription by the market maker to the issue (The "Market Maker Reservation Portion"). The public issue less market maker reservation portion i.e. issue of 15,27,600 equity shares of face value of Rs. 10/- each, at an issue price of Rs. [*] per equity share for cash, aggregating upto Rs. [*] crores is herein after referred to as the "Net Issue". The public issue and net issue will constitute [*] and [*] % respectively of the post-issue paid-up equity share capital of the company.
The price band and the minimum bid lot will be decided by the company. |
